Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 déc. 2014 09h30 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments That Combine Cell-in-a-Box(R) and Cannabinoid-Based Medicine

SILVER SPRING, Md., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today...
24 nov. 2014 08h30 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Announces the Formation of a Diabetes Consortium for the Development of Its Treatment for Insulin-Dependent Diabetes

SILVER SPRING, Md., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today...
21 nov. 2014 09h36 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Executives in Southeast Asia to Further Advance Cell-in-a-Box Technology(R)

SILVER SPRING, Md., Nov. 21, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today...
19 nov. 2014 09h30 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation

SILVER SPRING, Md., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today...
07 nov. 2014 09h30 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment

SILVER SPRING, Md., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases,...
20 oct. 2014 09h00 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Contracts With University of Veterinary Medicine in Vienna to Conduct Preclinical Studies on the Use of Cell-in-a Box(R) to Develop Diabetes Treatment

SILVER SPRING, Md., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases,...
16 oct. 2014 09h00 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Secures Worldwide License for Insulin-Producing Cells From University of Technology, Sydney, for Use in Developing Diabetes Treatment

SILVER SPRING, Md., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases,...
13 oct. 2014 09h00 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Applies to FDA for Orphan Drug Designation for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer

SILVER SPRING, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced...
06 oct. 2014 09h00 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Appoints Dr. Matthias Lohr as Chairman of Scientific Advisory Board

SILVER SPRING, Md., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today...
01 oct. 2014 09h00 HE | Source: PharmaCyte Biotech, Inc.

Nuvilex Announces Strategic Changes to Leadership Team and Appoints Prof. Dr. Walter H. Gunzburg as Chief Scientific Officer

SILVER SPRING, Md., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today...

Page précédente

Page suivante